Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology
MONROVIA, Calif. , June 8, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Raphael Clynes
View HTML
Toggle Summary Xencor to Present at Jefferies 2017 Global Healthcare Conference
MONROVIA, Calif. , May 30, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,
View HTML
Toggle Summary Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
MONROVIA, Calif. , May 11, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced today that XmAb®5871 has been granted
View HTML
Toggle Summary Xencor Reports First Quarter 2017 Financial Results
-- Phase 1 Data from Subcutaneous Administration Trial of XmAb®5871 Support Biweekly Dosing ---- Management to Host Conference Call Today at 4:30 p.m. ET --
View HTML
Toggle Summary Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
MONROVIA, Calif. , May 2, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter 2017
View HTML
Toggle Summary Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference
MONROVIA, Calif. , April 26, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,
View HTML
Toggle Summary Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
MONROVIA, Calif. , April 17, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Kevin Gorman , Ph.D., chief executive officer of Neurocrine
View HTML
Toggle Summary Xencor to Present at Oppenheimer 27th Annual Healthcare Conference
MONROVIA, Calif. , March 15, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat , Ph.D.,
View HTML
Toggle Summary Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders
MONROVIA, Calif. , March 6, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that Bruce L.A. Carter , Ph.D., will not stand for reelection to the
View HTML
Toggle Summary Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting
Abstracts available on the AACR Annual Meeting website
View HTML
Xencor © Copyright 2018